About Vaccinex

Vaccinex is a privately held clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies, therapeutic vaccines and other biologic products to treat serious diseases with unmet needs, including cancer, multiple sclerosis, and other autoimmune diseases.

Learn More 

Clinical Trials

VX15/2503 Phase I Clinical Trial in Adult Patients with Solid Tumors

Learn More  

Innovative Antibodies

Oncology VX15
VX35
Multiple Sclerosis VX15
Autoimmune Disease VX5

Novel Antibodies to
Clinically Validated Targets

Oncology BVX20
VX70
Inflammatory Disease VX30

NKT Vaccine Platform

Oncology and Infectious Disease VX25
Inflammatory Disease VX45

Technology Platform

Vaccinex has developed one of only a handful of major, commercial platforms for human antibody discovery. Our core technology provides for robust expression of full length IgG in mammalian cells and, when coupled with high-throughput selection, allows for the rapid identification of fully human monoclonal antibodies.

Learn More